Evaxion reports 75% ORR for EVX-01 plus pembrolizumab in advanced melanoma

Evaxion Biotech reported Phase II results for its personalized neoantigen cancer vaccine EVX-01, which achieved a 75% objective response rate when combined with pembrolizumab in advanced melanoma patients. The company said responses were durable with sustained vaccine-induced T-cell activity, but noted the results are based on a small study population.

Detected & updated continuously · Source: Nebula